logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in Hemophilia Patients Sangamo Therapeutics ( SGMO ) and Pfizer ( PFE ) updated results from the Phase 1/2 Alta study, evaluating investigational SB-525 gene...

Read More

July 8, 2019

0

Gilead's New Acquisition: An Important Step Forward Toward Building a Superior Cancer Franchise

Gilead Sciences (GILD ) has unsurprisingly agreed to acquire Cell Design Labs in a structured buy out valued for up to $567 million, including the shares of Cell Design Labs held by Kite, the CAR T firm that Gilead has...

Read More

December 8, 2017

0

Are Illumina's 2019 Challenges Transitory?

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina ( ILMN )  stock dropped 16% following the firm's announcement of preliminary revenue for the second quarter of the fiscal year 2019 and updated its 2019 revenue guidance. According to the...

Read More

July 12, 2019

0

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis ( EXEL ) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021;...

Read More

July 15, 2019

0

Great biotech news in a bizarre market. Incyte has two consecutive good news

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s bad is that all the accomplishments could not bring joy to the deserving investors. The reason is the unpersuasive crazy market behavior. We believe...

Read More

December 17, 2018

0

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech  about licensing rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network . The agreement does not include cystic fibrosis (CF)  transmembrane conductance regulator (CFTR)...

Read More

December 18, 2018

0

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

CiRA, Takeda  & T-CiRA Less than five years ago the Center for iPS Cell Research and Application (CiRA) 1   at Kyoto University and Takeda   Pharmaceutical ( TAK ) 2 established a research program. Today, Takeda and CiRA announced...

Read More

July 17, 2019

0

Prohost greetings and opinions

We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that Peace of Mind, Serenity  and Optimistic Feelings Replace Unwarranted Pessimistic, False Impressions   That Have No Root in America’s Reality We Love You All...

Read More

December 24, 2018

0

Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Stock Rallied Seattle Genetics ( SGEN ) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following: Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting...

Read More

July 17, 2019

0

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities There is no doubt that  Gilead Sciences ( GILD )   is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and every week, we heard news...

Read More

July 22, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 64
  • 65
  • 66
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy